We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agilent and Integrated DNA Technologies Sign Co-Marketing Agreement for qPCR Studies
News

Agilent and Integrated DNA Technologies Sign Co-Marketing Agreement for qPCR Studies

Agilent and Integrated DNA Technologies Sign Co-Marketing Agreement for qPCR Studies
News

Agilent and Integrated DNA Technologies Sign Co-Marketing Agreement for qPCR Studies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent and Integrated DNA Technologies Sign Co-Marketing Agreement for qPCR Studies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agilent Technologies Inc. and Integrated DNA Technologies (IDT) have partnered to provide a complete solution for qPCR studies. The combination of the Mx3005P qPCR system and Brilliant qPCR reagents from Agilent with PrimeTime qPCR Assays from IDT provides customers a fully supported solution for qPCR studies.

“The partnership provides the benefit of performing 5' nuclease probe assays with qPCR reagents that have been extensively tested against competitor reagents and assays,” said Scott O’Brien, product line manager in Agilent’s genomics division. “Customers will benefit from better technical support from the validation of the Mx system, Brilliant reagents and PrimeTime qPCR Assays together.”

Coupling PrimeTime qPCR Assays with the Brilliant master mix allows researchers to easily expand the scope of their research studies. The combination will provide a tool for validating discoveries resulting from next-generation sequencing (NGS) and copy number variation (CNV) studies.

PrimeTime allows for flexibility in assay design due to the variety of options available, including choices of scales, dye/quencher combinations and primer-to-probe ratios. The PrimeTime qPCR Assays are available in three scales, including the PrimeTime Mini, which is claimed by the company to provide a reduced cost-per-assay and allows researchers to study more assays across a fewer numbers of samples.

Agilent’s Brilliant II and Brilliant III Ultra-Fast qPCR and qRT-PCR Master Mix kits are developed to offer sensitivity for improved reproducibility of nucleic acid quantification. The combined product can provide the complete solution for gene expression studies and a wide array of growing qPCR applications.

“Agilent’s gene expression product line matches well with IDT’s qPCR assays,” said Stephen Gunstream, vice president of marketing and strategy at IDT. “We believe this combination will provide superior results for gene expression researchers.”
Advertisement